Keyphrases
Metformin
100%
Antidiabetic Drugs
100%
Cyclin D1 (CCND1)
100%
Antitumoral Effect
100%
Protein Level
18%
LNCaP
18%
Tumor Growth
9%
Xenograft
9%
Phosphorylation
9%
In Cancer
9%
Signaling Pathway
9%
Prostate Cancer Cells
9%
Protein Expression
9%
Epidemiological Study
9%
Tumor
9%
Induced Apoptosis
9%
Glucose Homeostasis
9%
In Vitro Study
9%
Small Interfering RNA (siRNA)
9%
Cell Viability
9%
Cancer Cells
9%
Intraperitoneal Injection
9%
Cancer Risk
9%
Antiproliferative Activity
9%
Kinase Cascade
9%
Epithelial Cell Line
9%
Catalytic Subunit
9%
Prostate Epithelial Cells
9%
Human Prostate Cancer Cells
9%
Mode of Action
9%
Antineoplastic Agents
9%
Cancer Cell Proliferation
9%
Proliferation in Vitro
9%
Muscle Glucose Uptake
9%
Normal Prostate
9%
Oral Treatment
9%
P27Kip1
9%
AMP Kinase
9%
PC-3
9%
DU145
9%
Strong Reduction
9%
Antidiabetic Agents
9%
AMPK Pathway
9%
Liver Glucose Production
9%
Fuel Level Sensor
9%
Medicine and Dentistry
In Vitro
100%
Glycon
100%
Antidiabetic Agent
100%
Cyclin D1
100%
Cancer Cell
27%
Prostate Cancer
18%
Malignant Neoplasm
18%
AMP-Activated Protein Kinase
18%
Neoplasm
9%
Tumor Progression
9%
Protein Expression
9%
Enzyme Active Site
9%
Cell Cycle
9%
Xenograft
9%
Programmed Cell Death
9%
Cell Proliferation
9%
Glucose Homeostasis
9%
Phosphotransferase
9%
Glucose Uptake
9%
Epithelial Cell Line
9%
Antiproliferative Activity
9%
Small Interfering RNA
9%
Cell Viability
9%
Adenosine Phosphate
9%
Gluconeogenesis
9%
Cell Signaling Pathway
9%
Pharmacology, Toxicology and Pharmaceutical Science
Metformin
100%
Antidiabetic Agent
100%
Cyclin D1
100%
Malignant Neoplasm
27%
Prostate Cancer
18%
Cell Viability
9%
Tumor Growth
9%
Small Interfering RNA
9%
Phosphotransferase
9%
Adenosine Phosphate
9%
Cyclin Dependent Kinase Inhibitor 1B
9%
Neoplasm
9%